Results 61 to 70 of about 5,648 (180)

Baseline total lesion glycolysis combined with interim positron emission tomography‐computed tomography is a robust predictor of outcome in patients with peripheral T‐cell lymphoma

Cancer Medicine, 2020
Background Peripheral T‐cell lymphoma (PTCL) represents a heterogeneous and rare subgroup of aggressive lymphomas that generally demonstrate poor clinical outcomes with conventional treatment.
Akihiro Kitadate, Kentaro Narita, Kouta Fukumoto, Toshiki Terao, Takafumi Tsushima, Hiroki Kobayashi, Yoshiaki Abe, Daisuke Miura, Masami Takeuchi, Youichi Machida, Kosei Matsue   +10 more
doaj   +1 more source

Therapeutic challenges in peripheral T-cell lymphoma

Molecular Cancer
Peripheral T-cell lymphoma (PTCL) is a rare and heterogeneous group of hematological malignancies. Compared to our knowledge of B-cell tumors, our understanding of T-cell leukemia and lymphoma remains less advanced, and a significant number of patients ...
Yunpeng Luan, Xiang Li, Yunqi Luan, Junyu Luo, Qinzuo Dong, Shili Ye, Yuejin Li, Yanmei Li, Lu Jia, Jun Yang, Dong-Hua Yang   +10 more
doaj   +1 more source

Targeting EZH2 in Cancer: From Molecular Mechanisms to Clinical Translation

MedComm – Oncology, Volume 5, Issue 2, June 2026.
The abnormal overexpression or gain‐of‐function mutations of EZH2 play a significant role in cancer occurrence and progression, highlighting the importance and potential of EZH2 as a cancer biomarker. Therefore, screening for effective and safe small‐molecule inhibitors, degraders, and natural compounds targeting EZH2 through preclinical cancer models ...
Xi Zhong, Jieni Li, Mingxuan Pan, Xiaoxue Ke, Hongjuan Cui   +4 more
wiley   +1 more source

Evolution of superhalogen properties in PtCln clusters

The Journal of Chemical Physics, 2012
We have systematically calculated the ground state geometries, relative stability, electronic structure, and spectroscopic properties of PtCln (n = 1–7) clusters. The bonding in these clusters is dominated by covalent interaction. In neutral clusters, chlorine atoms are chemically bound to Pt up to n = 5.
Joseph, Jorly, Pradhan, Kalpataru, Jena, Purusottam, Wang, Haopeng, Zhang, Xinxing, Ko, Yeon Jae, Bowen, Kit H., Jr.   +6 more
openaire   +4 more sources

Therapeutic options in peripheral T cell lymphoma

Journal of Hematology & Oncology, 2016
Peripheral T cell lymphoma (PTCL) is a rare and heterogeneous group of non-Hodgkin lymphomas with a very poor prognosis. The standard first-line treatments have resulted in unsatisfactory patient outcomes.
Yaping Zhang, Wei Xu, Hong Liu, Jianyong Li   +3 more
doaj   +1 more source

Characteristic analysis of peripheral T-cell lymphoma associated with autoimmune hemolytic anemia

Zhongguo aizheng zazhi, 2021
Background and purpose: The pathological type of lymphoma associated with autoimmune hemolytic anemia (AIHA) is more common in indolent B lymphoma than in diffuse large B-cell lymphoma (DLBCL) or peripheral T-cell lymphoma (PTCL).
何合胜, 杨玉琼, 刘银华, 靳小可, 徐又海, 姚军萍, 刘善浩, 严家炜, 黄东平   +8 more
doaj  

Putative Clonal Evolution in a PHF6‐Mutant T/NK‐Cell Lymphoproliferative Disorder With Selective Loss of a STAT5B‐Mutant Subclone

eJHaem, Volume 7, Issue 3, June 2026.
Mark Anthony Turingan, Cuihong Wei, Nihad Almokhtar, Abi Vijenthira, Hong Chang   +4 more
wiley   +1 more source

Research progress of PD-1/PD-L1 inhibitors in the treatment of peripheral T-cell lymphomas

Zhongguo aizheng zazhi, 2020
Peripheral T-cell lymphomas (PTCLs) are a group of highly heterogeneous and aggressive non-Hodgkin’s lymphoma (NHL). PTCL patients have poor prognosis and high rates of relapse under the current chemotherapy-based treatment.
LUO Qian, ZOU Liqun
doaj  

Lack of SMARCB1 expression characterizes a subset of human and murine peripheral T-cell lymphomas

Nature Communications
Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is a heterogeneous group of malignancies with poor outcome. Here, we identify a subgroup, PTCL-NOS SMARCB1- , which is characterized by the lack of the SMARCB1 protein and occurs more ...
Anja Fischer, Thomas K. Albert, Natalia Moreno, Marta Interlandi, Jana Mormann, Selina Glaser, Paurnima Patil, Flavia W. de Faria, Mathis Richter, Archana Verma, Sebastian T. Balbach, Rabea Wagener, Susanne Bens, Sonja Dahlum, Carolin Göbel, Daniel Münter, Clara Inserte, Monika Graf, Eva Kremer, Viktoria Melcher, Gioia Di Stefano, Raffaella Santi, Alexander Chan, Ahmet Dogan, Jonathan Bush, Martin Hasselblatt, Sylvia Cheng, Signe Spetalen, Alexander Fosså, Wolfgang Hartmann, Heidi Herbrüggen, Stella Robert, Florian Oyen, Martin Dugas, Carolin Walter, Sarah Sandmann, Julian Varghese, Claudia Rossig, Ulrich Schüller, Alexandar Tzankov, Martin B. Pedersen, Francesco A. d’Amore, Karin Mellgren, Udo Kontny, Venkatesh Kancherla, Luis Veloza, Edoardo Missiaglia, Virginie Fataccioli, Philippe Gaulard, Birgit Burkhardt, Oliver Soehnlein, Wolfram Klapper, Laurence de Leval, Reiner Siebert, Kornelius Kerl   +54 more
doaj   +1 more source

Phase II Trial of Romidepsin as Consolidation Therapy after Gemcitabine, Dexamethasone, and Cisplatin in Elderly Transplant-Ineligible Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma

Hematology Reports
Romidepsin is an important therapeutic option for patients with peripheral T-cell lymphoma (PTCL). However, the timing of romidepsin administration remains controversial.
Satoshi Yamasaki, Hiroatsu Iida, Akio Saito, Morio Matsumoto, Yoshiaki Kuroda, Tohru Izumi, Akiko M. Saito, Hiroaki Miyoshi, Koichi Ohshima, Hirokazu Nagai, Hiromi Iwasaki   +10 more
doaj   +1 more source